EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease

Yu Nakamura, Christine Strohmaier, Kaoru Tamura, Naoko Kataoka, Masayuki Nakano, Shoichiro Oda, Kazuma Nishimura, Akira Homma

Dementia and Geriatric Cognitive Disorders Extra · 29.09.2015 · 5 (3) · 361-374

DOI: 10.1159/000439269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders Extra, online erschienen am 29.09.2015. Verfasst von Yu Nakamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate whether 1-step titration of the rivastigmine patch (initiated at 5 cm2 and titrated to 10 cm2 after 4 weeks) is well tolerated in Japanese patients with Alzheimer's disease (AD) as compared to 3-step titration (initiated at 2.5 cm2 and titrated by 2.5 cm2 every 4 weeks to 10 cm2).

Methods

A 24-week, multicenter, randomized, double-blind study was conducted in Japan between July 2012 and May 2014. Patients with mild to moderate AD aged 50-85 years were randomized 1:1 to 1-step or 3-step titration of the rivastigmine once-daily patch. The primary endpoint was the proportion of patients with adverse events leading to discontinuation.

Results

Of 216 patients randomized, 215 (1-step, n = 107; 3-step, n = 108) were included in the safety analysis. The primary endpoint outcome was 15.0% in the 1-step group and 18.5% in the 3-step group. The observed treatment difference was −3.6% (95% confidence interval: −17.0, 9.6), falling within the prespecified acceptance range.

Conclusion

The tolerability of two different titration schemes was similar in Japanese patients with AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseCholinesterase inhibitorsJapanRandomized clinical trialRivastigmine patchTitration scheme

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharma K.K., Tokyo, Japan.
  • Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Dementia Care Research and Training Center, Tokyo, Japan.

Zitieren

APA

Nakamura, Y., Strohmaier, C., Tamura, K., Kataoka, N., Nakano, M., Oda, S., Nishimura, K., & Homma, A. (2015). A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 5(3), 361-374. https://doi.org/10.1159/000439269

Vancouver

Nakamura Y, Strohmaier C, Tamura K, Kataoka N, Nakano M, Oda S, et al. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra. 2015;5(3):361-374. doi:10.1159/000439269

BibTeX
@article{Nakamura2015,
  author = {Nakamura, Yu and Strohmaier, Christine and Tamura, Kaoru and Kataoka, Naoko and Nakano, Masayuki and Oda, Shoichiro and Nishimura, Kazuma and Homma, Akira},
  title = {A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease},
  journal = {Dementia and Geriatric Cognitive Disorders Extra},
  year = {2015},
  volume = {5},
  number = {3},
  pages = {361--374},
  doi = {10.1159/000439269}
}
Kostenlos starten →